The shares of Merck & Co., Inc. (NYSE:MRK) has been pegged with a rating of Buy by Citigroup in its latest research note that was published on October 16th, 2018. The research company has also assigned a $79 price target. Citigroup wasn’t the only research firm that published a report of Merck & Co., Inc., with other equities research analysts also giving their opinion on the stock. Guggenheim advised investors in its research note published on October 9th, 2018, to Buy the MRK stock. The stock had earned Buy rating from Goldman when it published its report on April 23rd, 2018. The stock was given Overweight rating by Morgan Stanley in its report released on April 17th, 2018. Barclays was of a view that MRK is Overweight in its latest report on April 5th, 2018 while giving it a price target of $64. Leerink Partners thinks that MRK is worth Outperform rating. This was contained in the firm’s report on March 12th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 3 believe it has the potential for further growth, thus rating it as Hold while 7 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $79.12. The price of the stock the last time has raised by 48.34% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 64.86.
The shares of the company added by 0.20% during the trading session on Thursday, reaching a low of $75.82 while ending the day at $78.37. During the trading session, a total of 16.4 million shares were traded which represents a -45.74% decline from the average session volume which is 11.25M shares. MRK had ended its last session trading at 78.21. Merck & Co., Inc. currently has a market cap of $208.62B, while its P/E ratio stands at 35.54, while its P/E earnings growth sits at 5.00, with a beta of 0.72. Merck & Co., Inc. debt-to-equity ratio currently stands at 0.73, while its quick ratio hovers at 1.20. MRK 52-week low price stands at $52.83 while its 52-week high price is $80.19.
The company in its last quarterly report recorded $1.19 earnings per share which is above the $1.14 predicted by most analysts. The Merck & Co., Inc. generated $10,794.00 million in revenue during the last quarter, which is slightly lower than the $10,880.30 million predicted by analysts. In the second quarter last year, the firm recorded $1.06 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 10.92%. Merck & Co., Inc. has the potential to record 2.21 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Credit Suisse published a research note on October 11th, 2018 where it informed investors and clients that Enterprise Products Partners L.P. (NYSE:EPD) is now rated as Outperform. Guggenheim also rated EPD as Resumed on October 9th, 2018, with its price target of $47 suggesting that EPD could surge by 23.23% from its current share price. Even though the stock has been trading at $26.21/share, analysts expect it to surge higher by -0.53% to reach $33.96/share. It started the day trading at $26.1 and traded between $25.34 and $26.07 throughout the trading session.
A look at its technical shows that EPD’s 50-day SMA is 27.43 while its 200-day SMA stands at 27.55. The stock has a high of $30.05 for the year while the low is $22.73. The company’s P/E ratio currently sits at 15.61, while the P/B ratio is 2.46. The company’s average trading volume currently stands at 4.78M shares, which means that the short-interest ratio is just 2.10 days. Over the past seven days, the company moved, with its shift of -0.04%. Looking further, the stock has dropped -9.98% over the past 90 days while it lost -11.24% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Harvest Fund Advisors LLC bought more EPD shares, increasing its portfolio by +4.87% during the last quarter. This move now sees Harvest Fund Advisors LLC purchasing 2,255,648 shares in the last quarter, thus it now holds 48,543,792 shares of EPD, with a total valuation of $1,301,944,501. Tortoise Capital Advisors LLC meanwhile bought more EPD shares in the recently filed quarter, changing its stake to $1,133,425,430 worth of shares. ALPS Advisors Inc followed the path by decreasing its EPD portfolio by -5.54% in the quarter. This means that ALPS Advisors Inc sold -2,053,664 shares in the last quarter and now controls 35,016,061 shares of the EPD stock, with the valuation hitting $939,130,756.
Similarly, Kayne Anderson Capital Advisors L decreased its Enterprise Products Partners L.P. shares by -0.10% during the recently filed quarter. After selling -30,865 shares in the last quarter, the firm now controls 30,343,490 shares of Enterprise Products Partners L.P. which are valued at $813,812,402. In the same vein, Fayez Sarofim Co increased its Enterprise Products Partners L.P. shares by during the most recent reported quarter. The firm bought 39,091 shares during the quarter which increased its stakes to 19,742,802 shares and is now valued at $529,501,950. Following these latest developments, around 0.20% of Enterprise Products Partners L.P. stocks are owned by institutional investors and hedge funds.